How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Hematology. American Society of Hematology. Education Program

• Publication date

  2014-12-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/asheducation-2014.1.268PMID 25696866
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.

  2014cited by this paper
• Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor

  2014cited by this paper
• JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.

  2014cited by this paper
• Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.

  2014cited by this paper
• Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia

  2014cited by this paper
• Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.

  2014cited by this paper
• Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase

  2014cited by this paper
• Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells

  2014cited by this paper
• A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression

  2013cited by this paper
• Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F Without Compromising Progenitor Cell Expansion

  2013cited by this paper
• Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia

  2013cited by this paper
• Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

  2013cited by this paper
• Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

  2013cited by this paper
• Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

  2013cited by this paper
• JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

  2013cited by this paper
• Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

  2013cited by this paper
• Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

  2013cited by this paper
• Myelofibrosis, JAK2 inhibitors and erythropoiesis

  2013cited by this paper
• Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis.

  2013cited by this paper
• Critical Roles of Myc-ODC Axis in the Cellular Transformation Induced by Myeloproliferative Neoplasm-Associated JAK2 V617F Mutant

  2013cited by this paper
• Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.

  2013cited by this paper
• Structure of a pseudokinase domain switch that controls oncogenic activation of Jak kinases

  2013cited by this paper
• Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans

  2013cited by this paper
• Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.

  2012cited by this paper
• Critical requirement for Stat5 in a mouse model of polycythemia vera.

  2012cited by this paper
• The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.

  2012cited by this paper
• JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.

  2012cited by this paper
• A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

  2012cited by this paper
• Identification of oncostatin M as a JAK2 V617F‐dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms

  2012cited by this paper
• Crystal structures of the Jak2 pseudokinase domain and the pathogenic mutant V617F

  2012cited by this paper
• JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

  2012cited by this paper
• Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.

  2012cited by this paper
• JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms

  2012cited by this paper
• Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms

  2011cited by this paper
• Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.

  2011cited by this paper
• Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy

  2011cited by this paper
• Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival

  2011cited by this paper
• The JAK2 V617F somatic mutation, mortality and cancer risk in the general population

  2011cited by this paper
• JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation.

  2011cited by this paper
• The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling

  2011cited by this paper
• Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.

  2011cited by this paper
• Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms.

  2011cited by this paper
• JAK2 V617F-Dependent Upregulation of PU.1 Expression in the Peripheral Blood of Myeloproliferative Neoplasm Patients

  2011cited by this paper
• Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

  2011cited by this paper
• Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

  2010cited by this paper
• Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders

  2010cited by this paper
• Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

  2010cited by this paper
• Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

  2010cited by this paper
• Cooperative epigenetic modulation by cancer amplicon genes.

  2010cited by this paper
• HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

  2010cited by this paper
• Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors*

  2010cited by this paper
• JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.

  2010cited by this paper
• Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.

  2009cited by this paper
• ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling.

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.

  2009cited by this paper
• VEGFR1-activity-independent metastasis formation

  2009cited by this paper
• Faculty Opinions recommendation of JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.

  2009cited by this paper
• Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage

  2009cited by this paper
• Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

  2009cited by this paper
• Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

  2009cited by this paper
• JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

  2009cited by this paper
• JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

  2008cited by this paper
• Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.

  2008cited by this paper
• The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

  2008cited by this paper
• Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F*

  2008cited by this paper
• The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.

  2008cited by this paper
• Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.

  2008cited by this paper
• Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-α 2a in a patient with polycythemia vera

  2007cited by this paper
• Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.

  2007cited by this paper
• Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.

  2007cited by this paper
• Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

  2007cited by this paper
• Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

  2007cited by this paper
• The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.

  2007cited by this paper
• Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation.

  2007cited by this paper
• STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice.

  2007cited by this paper
• JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

  2007cited by this paper
• Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor

  2007cited by this paper
• Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years.

  2007cited by this paper
• JAK2(V617F): Prevalence in a large Chinese hospital population.

  2007cited by this paper
• Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

  2006cited by this paper
• Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.

  2006cited by this paper
• The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera

  2006cited by this paper
• Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition*

  2006cited by this paper
• Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia

  2006cited by this paper
• The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.

  2006cited by this paper
• Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

  2006cited by this paper
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  2005influential reference
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005influential reference
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005influential reference
• Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

  2005cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005influential reference
• The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis.

  2005cited by this paper
• Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells.

  2005cited by this paper
• Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera.

  2002cited by this paper
• Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.

  1991cited by this paper
• Recombinant interferon-alpha for treatment of polycythaemia vera.

  1988cited by this paper
• Treatment of essential thrombocythaemia by alpha 2a interferon.

  1988cited by this paper
• Idiopathic myelofibrosis.

  1984cited by this paper

• Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers

  2026influential citation
• Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms

  2025cites this paper
• Loss of Function Mouse Models Reveal a Novel Regulatory Function for ULK1 in Myeloproliferative Neoplasms

  2025cites this paper
• CRISPR/Cas9-Based Modeling of JAK2 V617F Mutation in K562 Cells Reveals Enhanced Proliferation and Sensitivity to Therapeutic Agents

  2025cites this paper
• Malignant JAK-signaling: at the interface of inflammation and malignant transformation

  2025cites this paper
• Mutation Pathogenicity Prediction by a Biology Based Explainable AI Multi-Modal Algorithm

  2024cites this paper
• Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b

  2024cites this paper
• Genome sequencing of 2000 canids by the Dog10K consortium advances the understanding of demography, genome function and architecture

  2023cites this paper
• Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study

  2023cites this paper
• Molecular landscape of the JAK2 gene in chronic myeloproliferative neoplasm patients from the state of Amazonas, Brazil

  2023cites this paper
• Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling

  2023cites this paper
• Epigenetic regulation by ASXL1 in myeloid malignancies

  2023cites this paper
• Review: JAK2V617F Allele Burden in Diagnosis and Therapeutic Monitoring of Myeloproliferative Neoplasms

  2023cites this paper
• Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720‐2A>G variant

  2022cites this paper
• Novel JAK2 Exon 14 Mutations L611S or N622Y in cis with JAK2V617F Are Associated with Distinct Clinical Phenotype of Polycythemia Vera and Concurrent Eosinophilia

  2022cites this paper
• JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome

  2022cites this paper
• ASXL1/2 mutations and myeloid malignancies

  2022cites this paper
• Clonal Hematopoiesis, Somatic Mosaicism, and Age-Associated Disease.

  2022cites this paper
• Simultaneous detection of JAK2, CALR, and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe‐Tm method in i‐densy IS‐5320

  2022cites this paper
• Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis

  2022cites this paper
• Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.

  2022cites this paper
• Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells.

  2022cites this paper
• Murine models of clonal hematopoiesis to assess mechanisms of cardiovascular disease.

  2021cites this paper
• Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

  2021cites this paper
• Medical dilemmas – erythrocytosis

  2020cites this paper
• Fedratinib in myelofibrosis.

  2020cites this paper
• NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells

  2020cites this paper
• The Molecular Genetics of Myeloproliferative Neoplasms.

  2019cites this paper
• The Diagnostic Process of a Patient with Bilateral Physiological Blind Spot Enlargement

  2019cites this paper
• Non-receptor Tyrosine Kinases Role and Significance in Hematological Malignancies

  2019cites this paper
• Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia

  2018cites this paper
• Elucidating the role of JAK/STAT signalling in polycythaemia vera and essential thrombocythaemia using proteomics

  2018cites this paper
• Genetic susceptibility to myeloproliferative neoplasms and therapeutic efficacy

  2018influential citation
• Updates in Polycythemia Vera

  2018cites this paper
• The Fluctuations in Homocysteine Level Caused by Various Combinations of Folic Acid Cycle Genes Snp Alleles as a Factor in the Course of Pregnancy Violation

  2018cites this paper
• Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells

  2018cites this paper
• Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.

  2017cites this paper
• Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.

  2017cites this paper
• Heat shock protein 27 (HSP27/HSPB1) expression is increased in patients with primary and secondary myelofibrosis and may be affecting their survival

  2017cites this paper
• Signaling coupled epigenomic regulation of gene expression

  2017cites this paper
• Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study

  2016cites this paper
• Implicaciones clínicas y de pronóstico de la mutación JAK2 V617F en pacientes con neoplasias mieloproliferativas crónicas

  2016cites this paper
• New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape

  2016cites this paper
• Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

  2016cites this paper
• [Advances in research of essential thrombocythemia].

  2015cites this paper
• 原发性血小板增多症研究的新进展

  2015cites this paper